• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

Viral Hepatitis Blog

FDA Logo
The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.
Posted In: 
Prevention and Wellness
Public Health and Safety
Jim Berger, MS, MT (ASCP), SBB, Senior Advisor for Blood Policy
Earlier this month, we marked the 80th anniversary of the world’s first blood bank. It’s hard to overstate the importance of blood banking in the history of modern medicine, or the changes that have occurred in blood banking and transfusion in the last century.
Posted In: 
Prevention and Wellness
Public Health and Safety
A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report
A new report from the National Academies makes recommendations for eliminating hepatitis B & C in the U.S. by 2030, complementing National Viral Hepatitis Action Plan.
Posted In: 
Prevention and Wellness
Public Health and Safety
National Viral Hepatitis Action Plan thumbnail
Broad support and participation evident from 700+ participants in webinar on the National Viral Hepatitis Action Plan, 2017 -2020.
Posted In: 
Prevention and Wellness
Public Health and Safety
Image of African American patient
Black History Month is an opportunity to raise awareness of the impact of chronic hepatitis C infection in the African-American community.
Posted In: 
Prevention and Wellness
Public Health and Safety
National Viral Hepatitis Action Plan thumbnail
Join HHS and partners for a webinar on the National Viral Hepatitis Action Plan 2017 – 2020
Posted In: 
Prevention and Wellness
Public Health and Safety
Thumbnail image of HCV Consultation Report
In September 2016, HHS convened an expert consultation to discuss key issues and the evidence for early HCV treatment in the United States. The consultation summary and meeting slides are now available.
Posted In: 
Prevention and Wellness
Public Health and Safety
Thumbnail image of the national viral hepatitis action plan
The National Viral Hepatitis Action Plan 2017 – 2020 has been released
Posted In: 
Prevention and Wellness
Public Health and Safety
Headshot of doctors Wang and Gish
Offers a description of HBV reactivation that can occur alongside DAA treatment for HCV; discusses the new FDA black box warning for individuals starting DAA treatment for HCV; provide action steps for both patients and providers, in order to help prevent HBV reactivation and the negative health outcomes associated with it.
Posted In: 
Health Care
Prevention and Wellness
Public Health and Safety
Image from the comparison of HCV treatment costs report
A study, “Comparison of Hepatitis C Treatment Costs, Estimates of Net Prices and Usage in the U.S. and Other Major Markets,” was published by the IMS Institute for Healthcare Informatics.
Posted In: 
Medicare and Medicaid
Prevention and Wellness

Pages

  • of 29
  • >